domingo, abril 10, 2005
The Lancet em favor dos genéricos
Ensuring the safety of HIV/AIDS generics
Welcome news on the international HIV/AIDS front arrived recently when the US Food
and Drug Administration (FDA) approved Aspen Pharmacare's triple-antiretroviral
regimen. Tentative FDA approval for this South African company qualifies its triple
combination therapy for purchase with funds allocated by the US President's
Emergency Plan for AIDS Relief (PEPFAR). But the continuing criticism of generic
drugs to treat HIV and the ongoing imbroglio around the use of single-dose
nevirapine for the prevention of mother-to-child transmission reminds us that
life-saving medicine remains politicised in a realm where politics has no place.
(...)
Welcome news on the international HIV/AIDS front arrived recently when the US Food
and Drug Administration (FDA) approved Aspen Pharmacare's triple-antiretroviral
regimen. Tentative FDA approval for this South African company qualifies its triple
combination therapy for purchase with funds allocated by the US President's
Emergency Plan for AIDS Relief (PEPFAR). But the continuing criticism of generic
drugs to treat HIV and the ongoing imbroglio around the use of single-dose
nevirapine for the prevention of mother-to-child transmission reminds us that
life-saving medicine remains politicised in a realm where politics has no place.
(...)
